Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 3
1979 6
1980 4
1981 6
1982 3
1983 4
1984 3
1985 4
1986 2
1987 6
1988 6
1989 7
1990 5
1991 7
1992 8
1993 8
1994 7
1995 8
1996 18
1997 11
1998 4
1999 10
2000 8
2001 10
2002 5
2003 9
2004 6
2005 11
2006 6
2007 13
2008 14
2009 11
2010 18
2011 9
2012 12
2013 10
2014 6
2015 6
2016 5
2017 20
2018 13
2019 10
2020 11
2021 16
2022 20
2023 12
2024 18
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, Kasbohm S, Kainz A, Eskandary F, Doberer K, Patel UD, Dudani JS, Regele H, Kozakowski N, Kläger J, Boxhammer R, Amann K, Puchhammer-Stöckl E, Vietzen H, Beck J, Schütz E, Akifova A, Firbas C, Gilbert HN, Osmanodja B, Halleck F, Jilma B, Budde K, Böhmig GA. Mayer KA, et al. Among authors: halloran pf. N Engl J Med. 2024 Jul 11;391(2):122-132. doi: 10.1056/NEJMoa2400763. Epub 2024 May 25. N Engl J Med. 2024. PMID: 38804514 Clinical Trial.
Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study. Ekberg H, et al. Among authors: halloran pf. N Engl J Med. 2007 Dec 20;357(25):2562-75. doi: 10.1056/NEJMoa067411. N Engl J Med. 2007. PMID: 18094377 Free article. Clinical Trial.
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA. Doberer K, et al. Among authors: halloran pf. J Am Soc Nephrol. 2021 Mar;32(3):708-722. doi: 10.1681/ASN.2020071106. Epub 2020 Dec 18. J Am Soc Nephrol. 2021. PMID: 33443079 Free PMC article. Clinical Trial.
CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection.
Doberer K, Kläger J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA, Agis H, Reiter T, Reindl-Schwaighofer R, Wahrmann M, Cohen G, Haslacher H, Bond G, Simonitsch-Klupp I, Halloran PF, Böhmig GA. Doberer K, et al. Among authors: halloran pf. Transplantation. 2021 Feb 1;105(2):451-457. doi: 10.1097/TP.0000000000003247. Transplantation. 2021. PMID: 32235256
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.
Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, Duong van Huyen JP, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M. Haas M, et al. Among authors: halloran pf. Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21. Am J Transplant. 2018. PMID: 29243394 Free PMC article.
The Clinical Relevance of the Infiltrating Immune Cell Composition in Kidney Transplant Rejection.
Vaulet T, Callemeyn J, Lamarthée B, Antoranz A, Debyser T, Koshy P, Anglicheau D, Colpaert J, Gwinner W, Halloran PF, Kuypers D, Tinel C, Van Craenenbroeck A, Van Loon E, Marquet P, Bosisio F, Naesens M. Vaulet T, et al. Among authors: halloran pf. J Am Soc Nephrol. 2024 Jul 1;35(7):886-900. doi: 10.1681/ASN.0000000000000350. Epub 2024 Apr 19. J Am Soc Nephrol. 2024. PMID: 38640017
385 results